Third-line dovitinib in metastatic renal cell carcinoma

The Lancet Oncology

Volumn 15, Issue 3, 2014, Pages 245-246

  Schmidinger, Manuela ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; DOVITINIB; EVEROLIMUS; FIBROBLAST GROWTH FACTOR 2; MAMMALIAN TARGET OF RAPAMYCIN; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; DRUG APPROVAL; DRUG CHOICE; DRUG TARGETING; HUMAN; KIDNEY CARCINOMA; METASTASIS POTENTIAL; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; QUINOLONES;

EID: 84896717441     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70082-8     Document Type: Note

References (10)

1. Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M, de Bruïne AP VHL and HIF signaling in renal cell carcinogenesis. J Pathol 2010, 221:125-138.
2. NCCN clinical practice guidelines in oncology (NCCN guidelines) kidney cancer, version 2 NCCN guidelines, (accessed Feb 1, 2014). http://www.nccn.org/professionals/physicians_gls/pdf.
3. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
4. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378:1931-1939.
5. Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2013, published online Dec 2. 10.1200/JCO.2013.50.3961.
6. Bergers G, Hanahan D Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8:592-603.
7. Welti JC, Gourlaouen M, Powles T, et al. Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene 2011, 30:1183-1193.
8. Motzer RJ, Porta C, Vogelzang NJ, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol 2014, published online Feb 17. http://dx.doi.org/10.1016/S1470-2045(14)70030-0.
9. Hammers HJ, Verheul HM, Salumbides B, et al. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther 2010, 9:1525-1535.
10. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508.